Induction of apoptosis and regression of spontaneous dog melanoma following in vivo application of synthetic cyclin-dependent kinase inhibitor olomoucine

Anti-Cancer Drugs

Volumn 8, Issue 10, 1997, Pages 1007-1013

  Hajdúch, Marián ^a   Kolář, Zdeněk ^a   Novotný, Radko ^a   Harnuš, Jan ^b   Mihál, Vladimír ^a   Hlobílková, Alice ^a   Nosková, Věra ^a   Strnad, Miroslav ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

Author keywords

Apoptosis; Chemotherapy; Cyclin dependent kinase inhibitor; Malignant melanoma; Olomoucine

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; OLOMOUCIUE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CERVICAL LYMPH NODE; DOG; ENZYME INHIBITION; LIVER TOXICITY; LYMPH NODE METASTASIS; MALE; MELANOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION;

EID: 0031443193     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199711000-00012     Document Type: Article

References (21)

1. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211-9.
2. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 54: 1169-74.
3. Firpo EJ, Koff A, Solomon MJ, Roberts JM. Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 1994; 14: 4889-901.
4. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9: 639-49.
5. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 634.
6. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response do TGF-beta. Genes Dev 1995; 9: 1831-45.
7. Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939-52.
8. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. Mol Cell Biol 1995; 15: 2682-8.
9. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-6.
10. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppress tumorigenicity in vivo. Nat Med 1995; 1: 1052-6.
11. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine derivates. Eur J Biochem 1994; 224: 771-86.
12. Schulze-Gahmen U, Brandsen J, Jones HD, et al. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins 1995; 22: 378-91.
13. Ongkeko W, Ferguson DJP, Harris AL, Norbury C. Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci 1995; 108: 2897-904.
14. Abraham RT, Acquarone M, Andersen A, et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 1995; 83: 105-20.
15. Havlicek L, Hanus J, Vesely J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 1997; 40: 408-12.
16. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
17. Hajduch M, Mihal V, Minarik J, et al. Decreased in vitro chemosensitivity of tumor cells in patients suffering from malignant diseases with a poor prognosis. Cytotechnology 1996; 19: 243-5.
18. Benhattar J, Cerottini JP, Saraga E, Mettthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69: 190-2.
19. Aas T, Borresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer. Nat Med 1996; 2: 811-4.
20. Newcomb EW. p53 gene mutations in lymphoid diseases and their possible relevance to drug resistance, Leuk Lymph 1995; 17: 211-21.
21. Muro K, Ohtsu A, Boku N, et al. Association of p53 protein expression with responses and survival of patient with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol 1996; 26: 65-9.